The incidence, mortality and risk factors of prostate cancer

Česká verze

Authors: M. Nesvadba; Ch. P. Cmorej; A. Mamova; O. Slowik
Authors place of work: Vysoká škola zdravotníctva a sociálnej práce sv. Alžbety v Bratislave
Published in the journal: Epidemiol. Mikrobiol. Imunol. 65, 2016, č. 4, s. 211-214
Category: Souhrnné sdělení

Summary

Prostate cancer is a serious oncological disease in males. There has been a significant escalation in the incidence of this malignancy in the Czech Republic and in developed countries of Europe recently. Conversely, in countries with an altered health system, a minor increase in new cases of this disease is recorded. The causes of the high incidence of prostate cancer in developed countries appear to be the introduction of the prostate specific antigen (PSA) test and prostate biopsy, an aging population, and the consequent increased risk of cancer. The possible contribution of physical and chemical carcinogens associated with environmental pollution and negative lifestyle changes should not be forgotten either. The mortality rate for prostate cancer remains stable, with a slight decline in recent years. The article provides an overview of trends in the incidence and mortality of prostate cancer in the Czech Republic and Europe.

KEYWORDS:
Globocan 2012 – incidence – mortality – prostate cancer

Zdroje

1. Nádorová onemocnění [online]. 2007-12-6 [cit. 2016-01-05]. Dostupné na www: http://www.szu.cz/tema/prevence/nadorova-onemocneni.

2. Česká republika a rakovina v číslech [online]. 2011-08-21[cit. 2016-01-05]. Dostupné na www: http://www.linkos.cz/co-musite-vedet/ceska-republika-a-rakovina-v-cislech/.

3. de Martel C, Ferlay J, Franceschi S, et al. Global burden of cancers attributable to infections in 2008: a review and synthetic analysis. The Lancet Oncology 2012;13: 607–615.

4. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. International Journal of Cancer 2014. doi:10.1002/ijc.29210 PMID:25220842 Published online 9 October 2014.

5. Bosetti C, Bertuccio P, Chatenoud L, et al. Trends in mortality from urologic cancers in Europe, 1970–2008. Eur Urol 2011; 60(1): 1–15.

6. Karcinom prostaty [online]. 2012-11-20 [cit. 2016-01-05]. Dostupné na www: http://www.cus.cz/pro-pacienty/diagnozy/karcinom-prostaty/.

7. Jansson KF, Akre O, Garmo H, et al. Concordance of tumor differentia-tion among brothers with prostate cancer. Eur Urol 2012; 62(4): 656–661.

8. Hemminki K. Familial risk and familial survival in prostate cancer. World J Urol 2012; 30(2): 143–148.

9. Leitzmann MF, Rohrmann S. Risk factors for the onset of prostatic cancer: age, location, and behavioral correlates. Cin Epidemiol 2012; 4: 1–11.

10. Ilic D, Misso M. Lycopene for the prevention and treatment of benign prostatic hyperplasia and prostate cancer: a systematic review. Maturitas 2012; 72(4): 269–276.

11. Andriole GL, Bostwick DG, Brawley OW, et al. Effect of dutasteride on the risk of prostate cancer. N Engl J Med 2010; 362(13): 1192–1202.

12. Pastucha D, Horáková D, Janoutová G, et al. Epidemiologie metabolického syndromu a možnosti prevence pohybovou aktivitou. Epidemiol. Mikrobiol. Imunol. 2007; 56(4): 181–185.

13. Richman EL, Kenfield SA, Stampfer MJ, et al. Egg, red meat, and poultry intake and risk of lethal prostate cancer in the prostate-specific antigen-era: incidence and survival. Cancer Prev Res (Phila) 2011; 4(12): 2110–2121.

14. O nádorech prostaty [online]. 2014-12-05 [cit. 2016-01-05]. Dostupné na www: http://www.linkos.cz/zhoubne-nadory-muzskeho-pohlavniho-ustroji-c60-c62-1/o-nadorech-prostaty/.

15. Zdravotnická ročenka České republiky 2013 [online]. 2013 [cit. 2016-01-05]. Dostupné na www: http://www.uzis.cz/katalog/rocenky/zdravotnicka-rocenka-ceske-republiky.

16. Novotvary 2010 [online]. 2010 [cit. 2016-01-05]. Dostupné na www: http://www.uzis.cz/category/tematicke-rady/zdravotnicka-statistika/novotvary.

17. Predikce počtu léčených pacientů s nádory prostaty v ČR v roce 2014 [online].2014 [cit. 2016-01-05]. Dostupné na www: http://www.uroweb.cz/index.php?pg=dg--nadory-prostaty--predikce-lecby--predikce-poctu-lecenych-pacientu-s-nadory-prostaty-v-cr-v-roce-2014.

18. Dušek L, Mužík J, Kubásek M, Koptíková J, Žaloudík J, Vyzula R. Epidemiologie zhoubných nádorů v České republice [online]. Masarykova univerzita, 2005, [cit. 2016-4-06]. Dostupné na www: http://www.svod.cz. Verze 7.0 [2007], ISSN 1802 – 8861.

19. Forman D, Bray F, Brewster DH, Gombe Mbalawa C, Kohler B, Piñeros M, Steliarova-Foucher E, Swaminathan R, Ferlay J. Cancer Incidence in Five Continents, Vol. X [online] [01-11-2013]Lyon, IARC. Dostupné na www: http://ci5.iarc.fr last accessed on.

20. Hugosson J, Carlsson S, Aus G, et al. Mortality results from the Göteborg randomised population-based prostate-cancer screening trial. Lancet Oncol 2010; 11(8): 725–732.

21. Etzioni R, Gulati R, Cooperberg MR, et al. Limitations of basing screening policies on screening trials: The US Preventive Services Task Force and Prostate Cancer Screening. Med Care 2013; 51(4): 295–300.

22. Ilic D, Neuberger MM, Djulbegovic M, et al. Screening for prostate cancer. Cochrane Database Syst Rev 2013; 1: CD004720.

23. Karcinom prostaty [online]. 2007 [cit. 2016-04-06]. Dostupné na www: http://medicabaze.cz/index.php?&sec=term_detail&termId=2711&tname=Karcinom.